AHR and ovarian carcinoma: Moreover, localization of AHR in the nucleus of tumor cells has been associated with a worse outcome in patients with ovarian cancer, and the role of the AHR/ARNT/CYP-enzyme pathway [106,107] and AHR-driven TBP gene expression in carcinogenesis and cancer initiation, as well as its potential use, have been considered as therapeutic targets for better outcomes [108].